New drug combo trial offers hope for advanced stomach cancer patients
Disease control
Not yet recruiting
This study is testing whether a new drug combination (LM-108 plus toripalimab) works better than standard chemotherapy (paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has worsened after initial treatment. The trial will enroll 400 participan…
Phase: PHASE3 • Sponsor: LaNova Medicines Limited • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC